Sanofi Secures $1B Deal for Autoimmune Therapy Focused on Enjaymo
Sanofi has secured a landmark $1B deal to sell the global rights of its autoimmune therapy Enjaymo to Recordati. This autoimmune therapy specifically targets cold agglutinin disease, offering a promising treatment avenue for patients suffering from this condition.
Details of the Deal
The agreement allows Recordati to manage the distribution and commercialization of Enjaymo, which has shown efficacy in treating patients with cold agglutinin disease.
Strategic Industry Move
This transaction represents a significant strategic move by Sanofi as it focuses on enhancing its portfolio and expanding its reach in the pharmaceuticals market.
- Therapy: Enjaymo
- New Rights Holder: Recordati
- Deal Value: $1B
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.